Sebastiano Lava
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age (NCT06643442) | Sebastiano Lava | 2025-10-01 |
Track Sebastiano Lava automatically
Every clearance here is in the API, with alerts when new ones post.